Group 1 - The company held its 13th meeting of the third Supervisory Board on July 4, 2025, with all three supervisors participating, confirming the legality and validity of the meeting [1][2] - The Supervisory Board unanimously approved a resolution to participate in the auction for a 45% stake and corresponding debt of He Li Real Estate, aiming to improve operational efficiency and address office space constraints [1][2] - The company plans to acquire the real estate located at 1010-1016 Wai Ma Road, Huangpu District, Shanghai, with a land area of 1,492.20 square meters, to enhance its office space [1] Group 2 - The Supervisory Board also approved a resolution to provide financial assistance to He Li Real Estate, which has a good credit standing and low default risk, ensuring no harm to the company's main business or shareholder interests [2] - The financial assistance will be in the form of loans to support He Li Real Estate's daily operations and development [2]

Meeting Information - The company will hold its second extraordinary general meeting of shareholders on July 21, 2025, at 14:50 [1] - Network voting will be available on the same day from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 through the Shenzhen Stock Exchange trading system [1] Voting Procedures - Shareholders can choose between on-site voting or network voting, but not both; the first vote will be considered valid in case of duplicate voting [2] - Shareholders must be registered by the cut-off date of July 14, 2025, to participate in the meeting [2][3] Registration Details - Individual shareholders must present identification and stock account information for registration; authorized representatives must provide additional documentation [3][4] - Remote shareholders can register via email, fax, or mail, with a deadline of July 17, 2025, at 17:00 [4] Voting Process - All proposals for the meeting are non-cumulative voting proposals, and shareholders must indicate their voting preference as agree, oppose, or abstain [5][8] - Specific procedures for voting through the Shenzhen Stock Exchange trading system and internet voting system are provided [5] Additional Information - The company has provided templates for the authorization letter and shareholder registration form in the attachments [6][8]

Group 1 - The company held its 15th meeting of the 9th Board of Directors on June 20, 2025, with all 7 directors present, confirming compliance with legal regulations and company bylaws [1] - The board approved an adjustment to the bank merger loan plan, allowing the company to pay at least 319 million RMB from its own funds and up to 1.277 billion RMB through bank loans, increasing the loan amount from the previous plan [2] - The company plans to apply for the merger loan from several banks, including Bohai Bank, Industrial Bank, and China Minsheng Bank, with the final terms subject to bank approval [2] Group 2 - The board's voting results showed unanimous support for the proposal, with 7 votes in favor and no opposition or abstentions [3]

Core Insights - A new company, Qimu (Guangdong Hengqin) Pharmaceutical Technology Co., Ltd., has been established with a registered capital of 5 million RMB, fully owned by Xinjiang Qimu Pharmaceutical Research Institute [1] Company Overview - The legal representative of the company is Ji Zhihong [1] - The company is registered in Zhuhai, Guangdong, with its business address at 2682 North Ring Island Road, Hengqin [1] - The company is classified under the scientific research and technical services industry, specifically in research and experimental development [1] Shareholding Structure - Xinjiang Qimu Pharmaceutical Research Institute (Limited) holds 100% of the shares in Qimu (Guangdong Hengqin) Pharmaceutical Technology Co., Ltd. [1] Business Scope - The business scope includes medical research and experimental development, natural science research, technical services, technology development, and technology transfer [1] - Other activities include the manufacturing and sales of daily chemical products, health food, and disposable medical supplies [1] - The company is also involved in import and export activities, including technology import and export [1] Regulatory Compliance - The company is required to obtain approval for certain activities, such as food production and health food production, as per relevant regulations [1]

Core Viewpoint - The legal opinion letter confirms that the actual controller of Puris (Shanghai) Pharmaceutical Technology Development Co., Ltd., Lai Chunbao, has the legal qualifications to increase his shareholding in the company, and the increase complies with relevant laws and regulations [1][4][7] Group 1: Shareholding Situation - Before the increase, Lai Chunbao directly held 4,648,150 shares, accounting for 5.85% of the total share capital, while entities controlled by him held an additional 21,171,033 shares, representing 26.63% [4] - Lai Chunbao and his concerted actors collectively held 31,746,533 shares, which is 39.93% of the total share capital [4][7] Group 2: Increase Plan - The increase plan was announced on January 14, 2025, with a commitment to purchase shares worth no less than RMB 6 million and no more than RMB 9 million from January 15, 2025, to July 14, 2025 [5] - The actual increase involved the purchase of 224,800 shares, representing 0.28% of the total share capital, with a total expenditure of RMB 6,742,476.00 (excluding transaction fees) [5][6] Group 3: Information Disclosure - The company has fulfilled its information disclosure obligations regarding the increase, including announcements about the increase plan and its implementation [6][7] - A formal announcement regarding the completion of the increase is expected to be disclosed by June 10, 2025 [6] Group 4: Exemption from Tender Offer - The increase qualifies for exemption from the tender offer requirement as the total shareholding exceeded 30% prior to the increase, and the additional shares acquired did not exceed 2% of the total share capital [7]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on June 23, 2025, at 14:30, combining on-site voting and online voting [1][2] - Online voting will be available through the Shenzhen Stock Exchange trading system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Attendance - All shareholders registered by the close of trading on June 17, 2025, are entitled to attend the meeting and vote [2][3] - Shareholders can appoint proxies to attend the meeting, and the proxy does not need to be a shareholder [2][3] Agenda Items - The meeting will review a proposal to terminate certain fundraising projects and permanently supplement remaining raised funds into working capital [3][6] Registration and Documentation - Individual shareholders must present their ID and proof of shareholding to attend the meeting, while corporate shareholders must provide additional documentation [3][5] - Registration can also be done via mail or fax before the deadline [4][5] Voting Procedures - The voting will be non-cumulative, allowing shareholders to express their opinions as agree, disagree, or abstain [6] - The first valid vote will be considered for any repeated voting on the same proposal [6] Contact Information - The company’s securities department can be contacted for further inquiries, with provided contact details [5][8]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688393 证券简称：安必平 公告编号：2025-028 广州安必平医药科技股份有限公司 股东询价转让结果报告书暨持股5%以上股东权益变动 触及1%的提示性公告 诸暨高特佳睿安投资合伙企业（有限合伙）（以下简称"诸暨高特佳"）、重庆高特佳睿安股权投资基金 合伙企业（有限合伙）（以下简称"重庆高特佳"）、杭州高特佳睿海投资合伙企业（有限合伙）（以下 简称"杭州高特佳"）、杭州睿泓投资合伙企业（有限合伙）（以下简称" 杭州睿泓"）（诸暨高特佳、 重庆高特佳、杭州高特佳、杭州睿泓以下合称为"转让方"）保证向广州安必平医药科技股份有限公司 （以下简称"安必平""公司"）提供的信息内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ● 本次询价转让的价格为24.09元/股，转让的股票数量为1,871,500股。 ● 公司控股股东、实际控制人、董事、监事及高级管理人员不参与本次询价转让。转让方一致行动人王 海蛟为公司董事。 ● 本次 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 差异化分红的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海毕得医药科技股份有限公司（以下简称"毕得医药"或"公司"）首次公开 发行股票并在科创板上市持续督导期间的保荐机构，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》等有关法律法规和规范性 文件的要求，对毕得医药 2024 年度利润分配所涉及的差异化分红（以下简称"本 次差异化分红"）相关事项进行了核查，具体情况如下： 一、本次差异化分红的原因 公司第一次回购方案：2023 年 12 月 8 日召开第二届董事会第五次会议审议 通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用超 募资金及自有资金通过上海证券交易所交易系统以集中竞价交易方式进行回购 股份，回购的股份将全部用于员工持股计划或股权激励。回购股份价格不超过人 民币 95 元/股（含），回购的资金总额不低于人民币 5,000 万元（含），不超过 人民币 10,000 万元（含）。回购期限为自董事会审议通过本次回购方案之日起不 超过 12 个月。 公司第二次回购方 ...

独立董事提名人声明与承诺 西藏易明西雅医药科技股份有限公司 提名人西藏易明西雅医药科技股份有限公司董事会现就提名 冯岚 为西藏 易明西雅医药科技股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为西藏易明西雅医药科技股份有限公司第四届董事会独立 董事候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具 体声明并承诺如下事项： 一、被提名人已经通过西藏易明西雅医药科技股份有限公司第三届董事会提 名委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ?是□否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 ?是□否 如否，请详细说明：______________________________ 三、被提名人 ...

Transaction Overview - Hefei Lifan Pharmaceutical Co., Ltd. plans to transfer 2.2184% equity in Nanjing Mainowei Pharmaceutical Technology Co., Ltd. for a price of 22.183748 million RMB [1] - The company currently holds 6.4984% equity in Mainowei, which will decrease to 4.2800% after the transfer [1] - The transfer does not constitute a related party transaction or a major asset restructuring as per regulations [1] Counterparty Information - The buyer, Chengdu Yuanheyuandian Venture Capital Partnership, is a limited partnership established on November 6, 2023, with a registered capital of 1.961 billion RMB [2] - The main shareholders include several venture capital firms, with no significant conflicts of interest identified [2] Target Company Information - Nanjing Mainowei Pharmaceutical Technology Co., Ltd. was established on February 7, 2021, with a registered capital of 5.256734 million RMB [4] - The company reported total assets of 11.36144 million RMB and net assets of 8.73122 million RMB as of December 31, 2024 [4] - Mainowei's business includes the production of medical devices and pharmaceuticals, with recent financials showing a net loss of 3.12407 million RMB for the first quarter of 2025 [4] Agreement Details - The equity transfer agreement stipulates a payment structure where 50% of the transfer price is paid upfront and the remaining 50% within 15 working days after the first payment [5] - The agreement includes various conditions that must be met before the transfer is finalized, including due diligence and legal compliance [6][7] Impact on Company - The transaction is expected to generate a pre-tax profit of approximately 17.9876 million RMB, impacting the company's financials for 2025 [10] - The board believes the transaction is fair and will not adversely affect the company's operations or shareholder interests [10]